139 related articles for article (PubMed ID: 38440069)
1. Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization.
Öcal O; Kimm MA; Hoang TPT; Pech M; Öcal E; Ben Khaled N; Sangro B; Ricke J; Seidensticker M; Wildgruber M
JHEP Rep; 2024 Apr; 6(4):100995. PubMed ID: 38440069
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy.
D'Emic N; Engelman A; Molitoris J; Hanlon A; Sharma NK; Moeslein FM; Chuong MD
J Gastrointest Oncol; 2016 Apr; 7(2):269-77. PubMed ID: 27034796
[TBL] [Abstract][Full Text] [Related]
3. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
4. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
Ricke J; Schinner R; Seidensticker M; Gasbarrini A; van Delden OM; Amthauer H; Peynircioglu B; Bargellini I; Iezzi R; De Toni EN; Malfertheiner P; Pech M; Sangro B
J Hepatol; 2021 Dec; 75(6):1387-1396. PubMed ID: 34454995
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
Zhang L; Yan ZP; Hou ZH; Huang P; Yang MJ; Zhang S; Zhang S; Zhang SH; Zhu XL; Ni CF; Li Q
Front Mol Biosci; 2021; 8():624366. PubMed ID: 34124139
[No Abstract] [Full Text] [Related]
7. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G
J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087
[TBL] [Abstract][Full Text] [Related]
8. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
[TBL] [Abstract][Full Text] [Related]
10. Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers.
Gulmez A; Harputluoglu H
J Gastrointest Cancer; 2023 Mar; 54(1):11-19. PubMed ID: 35119620
[TBL] [Abstract][Full Text] [Related]
11. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
[TBL] [Abstract][Full Text] [Related]
12. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.
Surov A; Thormann M; Hinnerichs M; Seidensticker M; Seidensticker R; Öcal O; Schütte K; Zech CJ; Loewe C; van Delden O; Vandecaveye V; Verslype C; Gebauer B; Sengel C; Bargellini I; Iezzi R; Berg T; Klümpen HJ; Benckert J; Gasbarrini A; Amthauer H; Sangro B; Malfertheiner P; Omari J; Wienke A; Ricke J; Pech M
Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37219875
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors in Locally Advanced Rectal Cancer.
Duque-Santana V; López-Campos F; Martin-Martin M; Valero M; Zafra-Martín J; Couñago F; Sancho S
Oncology; 2023; 101(6):349-357. PubMed ID: 36273439
[TBL] [Abstract][Full Text] [Related]
15. Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma.
Sprinzl MF; Kirstein MM; Koch S; Seib ML; Weinmann-Menke J; Lang H; Düber C; Toenges G; Zöller D; Marquardt JU; Wörns MA; Galle PR; Vogel A; Pinter M; Weinmann A
Liver Cancer; 2019 Oct; 8(5):387-402. PubMed ID: 31768347
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Aspects and Inflammation-Immune Markers in Alcohol and/or Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients Treated With Sorafenib.
Pinto TAM; Saito HPA; Nourani CL; Ataide EC; Boin IFSF; Lourenco GJ; Lima CSP
Gastroenterology Res; 2024 Feb; 17(1):23-31. PubMed ID: 38463146
[TBL] [Abstract][Full Text] [Related]
17. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
Seidensticker M; Öcal O; Schütte K; Malfertheiner P; Berg T; Loewe C; Klümpen HJ; van Delden O; Ümütlü MR; Ben Khaled N; de Toni EN; Seidensticker R; Aghdassi A; Tran A; Bronowicki JP; Peynircioglu B; Sangro B; Pech M; Ricke J
JHEP Rep; 2023 May; 5(5):100699. PubMed ID: 36968218
[TBL] [Abstract][Full Text] [Related]
18. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial.
Shuen TWH; Alunni-Fabbroni M; Öcal E; Malfertheiner P; Wildgruber M; Schinner R; Pech M; Benckert J; Sangro B; Kuhl C; Gasbarrini A; Chow PKH; Toh HC; Ricke J
Clin Cancer Res; 2022 Sep; 28(17):3890-3901. PubMed ID: 35763041
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis.
Liu L; Gong Y; Zhang Q; Cai P; Feng L
Front Oncol; 2019; 9():1557. PubMed ID: 32064238
[No Abstract] [Full Text] [Related]
20. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O; Schütte K; Kupčinskas J; Morkunas E; Jurkeviciute G; de Toni EN; Ben Khaled N; Berg T; Malfertheiner P; Klümpen HJ; Sengel C; Basu B; Valle JW; Benckert J; Gasbarrini A; Palmer D; Seidensticker R; Wildgruber M; Sangro B; Pech M; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Feb; 148(2):475-485. PubMed ID: 33855585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
